Literature DB >> 12514183

Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling.

Baskaran Govindarajan1, Xianhe Bai, Cynthia Cohen, Hua Zhong, Susan Kilroy, Gwendolyn Louis, Marsha Moses, Jack L Arbiser.   

Abstract

Malignant melanoma is the cancer with the most rapid increase in incidence in the United States. Ultraviolet light and deficiency of the p16ink4a gene are known factors that predispose one to the development of malignant melanoma. The signal transduction pathways that underlie the progression of melanoma from their precursors, atypical nevi, are not well understood. We examined activation of the MAP kinase pathway in atypical nevi and melanoma cells and found that this pathway is activated in melanomas. To determine the functional significance of this activation, we introduced constitutively active MAP kinase kinase (MAPKK) into immortalized melanocytes. The introduction of this gene into melanocytes leads to tumorigenesis in nude mice, activation of the angiogenic switch, and increased production of the proangiogenic factor, vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs). Activation of MAP kinase signaling may be an important pathway involved in melanoma transformation. Inhibition of MAP kinase signaling may be useful in the prevention and treatment of melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514183     DOI: 10.1074/jbc.M212929200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

Authors:  Francesca Cerimele; Traci Battle; Rebecca Lynch; David A Frank; Emma Murad; Cynthia Cohen; Nada Macaron; John Sixbey; Kenneth Smith; Randolph S Watnick; Aristidis Eliopoulos; Bahig Shehata; Jack L Arbiser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

Review 2.  Application of angiogenesis to clinical dermatology.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Adv Dermatol       Date:  2008

3.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

4.  Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.

Authors:  L Zhuang; C S Lee; R A Scolyer; S W McCarthy; A A Palmer; X D Zhang; J F Thompson; L P Bron; P Hersey
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 5.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

6.  Gpnmb is a melanoblast-expressed, MITF-dependent gene.

Authors:  Stacie K Loftus; Anthony Antonellis; Ivana Matera; Gabriel Renaud; Laura L Baxter; Duncan Reid; Tyra G Wolfsberg; Yidong Chen; Chenwei Wang; Megana K Prasad; Seneca L Bessling; Andrew S McCallion; Eric D Green; Dorothy C Bennett; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2008-11-01       Impact factor: 4.693

7.  Effects of bavachin and its regulation of melanin synthesis in A375 cells.

Authors:  Jing-Hua Wang; Yuan-Yuan Pei; Hong-Dan Xu; Li-Jing Li; Ye-Qiu Wang; Guo-Liang Liu; Yan Qu; Ning Zhang
Journal:  Biomed Rep       Date:  2016-05-20

8.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

9.  Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells.

Authors:  Clelia Domenzain-Reyna; Daniel Hernández; Laia Miquel-Serra; María José Docampo; Celia Badenas; Angels Fabra; Anna Bassols
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

10.  Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.

Authors:  Seung-Shick Shin; Jin Namkoong; Brian A Wall; Ryan Gleason; Hwa Jin Lee; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-23       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.